![Mike Norris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mike Norris
Plus aucun poste en cours
Profil
Mike Norris is Vice President of Corporate Development for CardioVascular BioTherapeutics, Inc. Previously, he was Vice President of Strategy, Enablement and Measurement for Digitas, Inc. Mr. Norris worked with Xerox, the Associates, American Century, JC Penny Insurance and Williams-Sonoma.
Prior to joining Digitas, he was a Senior Manager of KPMG Consulting and Chief Executive Officer of MedQuest.
Mr. Norris received a BS and an MS in Electrical Engineering from the University of Illinois, Urbana, and an MBA from the University of St. Thomas, Houston, Texas.
Anciens postes connus de Mike Norris
Sociétés | Poste | Fin |
---|---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Formation de Mike Norris
University of Illinois | Graduate Degree |
University of St. Thomas (Texas) | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |